What is the next earnings date for MACK stock?
MERRIMACK PHARMACEUTICALS IN (MACK) will report earnings on 2024-08-01, after the market close.
MERRIMACK PHARMACEUTICALS IN (MACK) Forecast, Price Target & Analyst Ratings
NASDAQ:MACK • US5903282094
Current stock price
15.13 USD
0 (0%)
At close:
15.16 USD
+0.03 (+0.2%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MERRIMACK PHARMACEUTICALS IN (MACK).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
$0.00
Upside
-100.00%
From current price of $15.13 to mean target of $0.00, Based on 8 analyst forecasts
Low
$0.00
Median
$0.00
High
$0.00
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
45.00%
MACK was analyzed by 8 analysts. The buy percentage consensus is at 45. So analysts seem to be rather negative about MACK.
In the previous month the buy percentage consensus was at a similar level.
MACK was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Aug 1, 2024
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | ||||||||||
| EBITDA YoY % growth | -141.85M | -136.7M 3.63% | -90.48M 33.81% | -61.53M 32.00% | -20.27M 67.06% | -4.9M 75.83% | N/A | N/A | N/A | |
| EBIT YoY % growth | -145.1M | -141.6M 2.41% | -95.7M 32.42% | -65.6M 31.45% | -22.5M 65.70% | -4.9M 78.22% | -2.6M 46.94% | -2.1M 19.23% | -2.176M -3.62% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -13.20 | -12.10 8.33% | -8.45 30.17% | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
MERRIMACK PHARMACEUTICALS IN / MACK Forecast FAQ
How many analysts cover MERRIMACK PHARMACEUTICALS IN (MACK) stock?
The number of analysts covering MERRIMACK PHARMACEUTICALS IN (MACK) is 8.